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Abstract
Background: Tranexamic acid (TXA) is commonly used in orthopedic surgery to reduce excessive bleeding and
transfusion requirements. Our aim was to examine if TXA was required in all osteoarthritis patients undergoing TKA
surgery, and its possible effects on systemic inflammation and coagulation properties.
Methods: Twenty-three patients (Oxford Score 22–29) were recruited consecutively; 12 patients received TXA
before (IV, 1.2 g/90 kg) and immediately after surgery (intra-articular, 1.4 g/90 kg). Inflammatory mediators and
ROTEM parameters were measured in blood at baseline, after the first bone-cut, immediately after surgery, and
postoperative days 1 and 2.
Results: After the bone cut and surgery, TXA significantly increased MCP-1, TNF-α, IL-1β and IL-6 levels compared
to non-TXA patients, which was further amplified postoperatively. During surgery, TXA significantly prolonged
EXTEM clot times, indicating a thrombin-slowing effect, despite little or no change in clot amplitude or fibrinogen.
TXA was associated with three- to fivefold increases in FIBTEM maximum lysis (ML), a finding counter to TXA’s
antifibrinolytic effect. Maximum lysis for extrinsic and intrinsic pathways was < 8%, indicating little or no
hyperfibrinolysis. No significant differences were found in postoperative hemoglobin between the two groups.
Conclusions: TXA was associated with increased systemic inflammation during surgery compared to non-TXA
patients, with further amplification on postoperative days 1 and 2. On the basis of little or no change in viscoelastic
clot strength, fibrinogen or clot lysis, there appeared to be no clinical justification for TXA in our group of patients.
Larger prospective, randomized trials are required to investigate a possible proinflammatory effect in TKA patients.
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Background
A common perioperative complication during knee and
hip surgery is excessive bleeding and the need for blood
products [1, 2]. Serine protease inhibitor aprotonin was
removed from world markets in 2007 and led to
renewed interest in tranexamic acid (TXA) for reducing
blood loss during major surgery [3, 4]. TXA is a syn-
thetic lysine analog that reduces active bleeding by
blocking the 5 lysine-binding sites on plasminogen,
which prevents plasmin formation and decreases fibrinoly-
sis [3, 5]. TXA has a plasma half-life of ~ 2 h, and its antifi-
brinolytic effects may last up to 7–8 h in the circulation,
and ~ 17 h in most tissues [6].
In orthopaedic surgery, two injections of TXA are
commonly used; one is given intravenously before the
operation, and another in the knee joint on deflation of
the tourniquet [7–9]. In a recent large retrospective
cohort study, involving 872,416 patients, Poeran and
colleagues concluded that TXA was effective in reducing
the need for blood transfusions during total hip or knee
arthroplasty [10]. However, despite the overwhelming
evidence, the same authors cautioned that “we cannot
provide support for the ubiquitous use of TXA in all
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patients requiring joint arthroplasty, as the differential
impact on complications among patient subpopulations
remains to be studied” [10]. A number of ongoing con-
cerns include timing, dose, route of delivery (IV, oral,
topical), and whether all patients should receive the drug
[2, 8, 11]. Furthermore, there remains the risk of
thromboembolic events [3, 12], and there is an increased
awareness in the literature that TXA-specific lysine resi-
dues are not specific to reducing blood loss [13], but are
involved in other metabolic and signalling events,
protein-protein interactions and post-translational modi-
fications [14]. In some cases, TXA can increase bleeding
in brain independent of the tPA effect by binding to
plasminogen in the presence of increased levels of uro-
kinase plasminogen activator (uPA), which facilitates
plasmin formation and the propensity to bleed [4, 15].
In 2017, we also showed that TXA administration in
medium-risk cardiac surgery patients led to anomalous
clot behaviour after a sternotomy, lower platelet num-
bers after surgery, and little or no difference in fibrinoly-
sis compared to non-TXA patients [16].
A number of studies and many reviews have suggested
that TXA may have anti-inflammatory properties via inhib-
ition of plasmin-mediated activation of complement, mono-
cytes, and neutrophils and may also improve platelet
function [17, 18]. However, the evidence is weak, and since
mediators of inflammation are associated with increased risk
of thrombosis, and vice versa [13, 19], further studies are
warranted. We hypothesized based on our previous cardiac
surgery study [16] that TXA may have anomalous effects on
coagulation properties during surgery, alter the patient’s
inflammatory status and may not be required for all TKA
patients. Thus, the aim of the present study was to examine
the effects of TXA on coagulation and inflammation prior
to, during, and following surgery, and assess if TXA was
required in all patients undergoing elective TKA surgery.
Methods
Approvals
Informed consent was obtained prospectively from all par-
ticipants, and the study was approved by the Institutional
Human Research Ethics Committee (MHS20140812-03).
The research undertaken strictly adhered to the Code of
Ethics (Declaration of Helsinki) of the World Medical
Association for trials involving humans. This study was an
analytic, prospective, observational cohort (level II)
investigation in which patient groups were separated
non-randomly by treatment, with exposure occurring
after the initiation of anesthesia.
Subjects and procedures
Twenty-three patients (6 male, 17 female) undergoing
TKA across three private practices were recruited to
participate in the study (Table 1). The inclusion
criteria were patients who were diagnosed with pri-
mary knee osteoarthritis (OA). The exclusion criteria
were patients with (1) rheumatoid OA, (2) auto-
immune disorders, (3) recent or recurrent infections
with antibiotic treatment, or (4) contraindication for TXA
use (thrombotic disorder and hematuria). Two of the
three surgeons routinely use TXA perioperatively, and the
remaining surgeon performed all surgeries for the
non-TXA group.
All patients with exception of one TXA patient received
both spinal and general anesthesia (Table 1). The
anesthetic procedure included intravenous administration
midazolam (0.02 mg/kg) and propofol target-controlled
infusion (2–5 mg/kg/h) with fentanyl (75–85 μg) as
required. A tourniquet was inflated prior to the first
midline skin incision and a medial parapatellar access
was used to expose the joint capsule. After the bone
cut, an intra-articular cocktail comprising Ropivacaine
(400 mg), Ketorolac (30 mg), Adrenaline (1 mg), and
Methylprednisolone (40 mg) in a total volume of
200 ml of saline was injected into the sub-synovial
space, ligaments and muscles around the knee. All
unilateral TKA surgery was assisted with Precision
Computer Navigation (Stryker®). Implanted prosthesis
Table 1 Demographics, comorbidities and pre-operative,
perioperative and post-operative values (6 weeks) in non-TXA
and TXA groups
Non-TXA TXA p value
Age (years) 69 ± 1 65 ± 1 0.092
Weight (kg) 91 ± 5 90 ± 6 0.930
No. of patients 11 12
Gender M = 4 M = 2
F = 7 F = 10
Osteoarthritis 11 12
TXA administration:
IV Infusion (mg/kg) NA 13.5 ± 0.6
IA Injection (mg/kg) NA 15.5 ± 0.7
Preoperative:
Hemoglobin (HgB) g/L 136 ± 4 137 ± 4 0.980
Anesthetic:
General only 0 1
General + Spinal 11 11
Perioperative:
Tourniquet time (Min) 62 ± 11 27 ± 6 0.023*
Surgical time (Min) 107 ± 6 104 ± 4 0.566
Postoperative:
HgB g/L day 1 121 ± 3§ 122 ± 3§ 0.787
HgB g/L day 2 111 ± 2§ 121 ± 5§ 0.093
Data represent mean ± SEM *p < 0.05 between non-TXA and TXA group;
§p < 0.05 compared to preoperative value
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(cruciate retaining) were cemented (PALACOS® R+G),
Heraeus Medical, Germany). After implantation and
tourniquet deflation, the capsule was closed.
TXA administration
Following induction of anesthesia and prior to skin inci-
sion, an intravenous bolus injection of TXA (1.2 g per
90-kg patient) was administered (Fig. 1, Table 1). After the
operation and before skin closure, a second TXA bolus
(15.5 g/kg body wt.) was injected in the intra-articular
space in saline (i.e., 1.0 g TXA/10 ml saline).
Clinical assessments
Patients were assessed preoperatively and followed up at
6 weeks postoperative for clinical assessments (goniom-
etry for range of movement (ROM) as well as pain
scores), and patient reported outcome measures, which
included the Knee injury and Osteoarthritis Outcomes
Score (KOOS), Oxford Knee Score (OKS), EuroQol
(EQ-5D 3L) and Forgotten Joint Score (FJS) (Table 1).
Practice nurses used the Angulus ROM iPhone app,
which provides flexion and extension values by record-
ing and measuring movement in both a horizontal and
vertical plane.
Blood sampling
Peripheral venous blood was collected from patients at
three time points: (1) baseline, prior to anesthesia, (2) ~
10 min after the first bone cut, and (3) ~ 30 min follow-
ing skin closure. Blood was also collected from patients
on days 1 and 2 postoperative. Whole blood (1.8 ml)
was collected in 3.2% sodium-citrate vacutainers (BD
Australia) for coagulation assessment, and 4 ml was
collected into K2EDTA vacutainers (BD Australia) and
centrifuged (1500 rpm, 15 min, 4 °C). Plasma was re-
moved and snap-frozen in liquid nitrogen and stored
at − 80 °C for cytokine measurements.
Rotational thromboelastometry
Rotational thromboelastometry (ROTEM®, Tem Inter-
national, Munich, Germany) was performed on ROTEM®
delta according to the manufacturer’s instructions and
described in Letson and Dobson [20] and Solomon and
colleagues [21] (Fig. 2). Assays were run for 60 min.
Hyperfibrinolysis was defined as a maximum lysis index
greater than or equal to 15% [20, 22].
Cytokine analysis
Milliplex® Human Cytokine/Chemokine Magnetic Bead
Panel (Lot #: 2875005, Abacus ALS, Meadowbrook,
Queensland) in combination with the Magpix® analyser
(Luminex Corporation, Austin, Texas, USA) were used
to measure plasma levels of monocyte chemotactic pro-
tein (MCP)-1, tumor necrosis factor alpha (TNF-α),
interleukin (IL)-6, IL-8, IL-1β, IL-1 receptor antagonist
(IL-1RA), IL-4 and IL-10 at baseline, 10 min after bone
cut, in recovery, and on days 1 and 2 after surgery.
Assays were carried out according to the manufacturer’s
instructions with samples measured in duplicate. Detec-
tion ranges for all analytes were 3.2–10,000 pg/ml. Assay
sensitivities (minimum detectable concentration, pg/ml),
intra-assay precision (%CV) and inter-assay precision (n =
6 assays; %CV) for each analyte were MCP-1: 1.9, 1.5, 7.9;
TNFα: 0.7, 2.6, 13.0; IL-6: 0.9, 2.0, 18.3; IL-8: 0.4, 1.9, 3.5;
IL-1β: 0.8, 2.3, 6.7; IL-1RA: 8.3, 2.1, 10.7; IL-4: 4.5; 2.9,
14.7; IL-10: 1.1, 1.6, 16.8.
Statistics
A priori power analysis to determine sample sizes was
conducted using G-power3 program to minimize type 1
errors and was based on differences between coagulation
parameters prior to and at surgery end [16]. A sample
size of 10 patients in each group was sufficient for statis-
tically valid comparisons to be made with respect to
TXA vs non-TXA treatments with the power set at 0.8
Fig. 1 Summary of the study design and blood sampling times. Arterial blood was collected for rotational thromboelastometry (ROTEM) and
measurement of plasma inflammatory cytokines and chemokines at (1) baseline before anesthesia, (2) 10 min after bone cuts, and (3) end of
surgery (30 min after skin closure). Sampling was also conducted on days 1 and 2 postoperatively for routine hematology and inflammatory
cytokine/chemokine assessment
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and alpha level at 0.05. SPSS Statistics 24.0 was used for
all data analysis (IBM, Armonk, NY). Data normality
was assessed using Shapiro-Wilks test, with Levene’s test
used to determine equality of variances. Independent
samples t tests were used for between-groups com-
parison for normally distributed data. Within group
differences were analysed with paired samples t tests.
Non-normally distributed data was compared using a
Mann-Whitney U test. MILLIPLEX Analyst 5.1 soft-
ware (Luminex Corporation, Austin, Texas, USA),
which analyses data with a 5 parametric logistic
weighted curve fit, was used to determine cytokine
concentrations. Area under the curve (AUC) was
determined for changes in plasma cytokine levels
across each of the five time points assessed. The mean
AUC for each cytokine was compared for non-TXA
and TXA patients using an independent-t test with
Welch’s correction. All values are expressed as mean
± standard error of the mean (SEM) with significance
set at p < 0.05.
Fig. 2 Schematic of a ROTEM Trace showing the key coagulation parameters measuring clot initiation, propagation and clot breakdown or lysis,
and definitions of the major ROTEM parameters used in the study
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Results
Perioperative characteristics
There were no significant preoperative differences in
patient demographic or clinical parameters (Table 1).
Tourniquet time was significantly less in TXA patients
compared to non-TXA patients, with no significant
differences in surgical times (Table 1). Lower tourni-
quet times may be due to differences in surgical pro-
cedures among surgeons; however, it is important to
note that possible longer ischemic times in non-TXA
patients may exacerbate postoperative inflammation;
however, it was less than TXA-treated patients in our
cohort (see below). No differences in preoperative
knee biomechanic measures were observed, with the
exception of significantly higher extension (5° vs. 2°)
in the non-TXA group (Table 2). At 6 weeks postoper-
ative, patients within each group demonstrated signifi-
cant improvements in KOOS measures compared to
baseline, with no significant differences between
scores for non-TXA and TXA patients (Table 2).
Inflammatory status before, during and following surgery
There were no significant differences in baseline plasma
inflammatory mediators between non-TXA and TXA
patients (Fig. 3). At surgery end and postoperative days
1 and 2, patients that received TXA had significantly
higher plasma levels of MCP-1 compared to non-TXA
patients (Fig. 3). Area-under-the-curve (AUC) analysis
over 3 days supported this finding (p = 0.013) (Fig. 4).
TNF-α was also significantly higher in TXA patients at
each of the time points assessed (Fig. 3), and supported
by AUC analysis (p = 0.010). IL-6 was significantly higher
immediately after surgery and 1.8-times higher than
non-TXA group on day 2 postoperative, but did not
reach significance. Similarly, IL-8, a chemokine at-
tractant for neutrophils and lymphocytes, and indu-
cible by TNF-α and IL-1β [23], was 1.8 times higher
on day 2 (p = 0.085) in TXA versus non-TXA patients.
Levels of IL-1β, an inflammation amplifier, were also
elevated in plasma of TXA patients after the first bone cut
and at surgery end (Fig. 3). However, despite a ninefold in-
crease in IL-1β in TXA patients compared to the
non-TXA group at day 2 postoperative (Fig. 3) and a
threefold higher AUC value (Fig. 4; p = 0.064), these differ-
ences were not significant. Plasma levels of IL-1RA
remained unchanged throughout surgery through to post-
operative day 2 (Fig. 3). Plasma IL-4 levels were higher in
TXA patients compared to non-TXA patients after the
first bone cut and at surgery end, with levels continuing to
increase on day 2. The AUC for IL-4 was significantly
higher (8 times) for TXA than non-TXA patients (p =
0.042, Fig. 4). After surgery, the anti-inflammatory
cytokine IL-10 peaked in both patient groups, and
then decreased on days 1 and 2, with a trend toward
higher values of IL-10 in plasma from non-TXA com-
pared to TXA patients (1.45 to 2.2 times higher) (Fig. 3).
Coagulation parameters
EXTEM
In non-TXA patients after the first bone cut and at
surgery end, CT and α-angles were similar to baseline
(Table 3), although CFTs fell by ~ 20% (96 to 76 s)
suggesting a slowing of clot elongation (Fig. 2). Clot
amplitudes underwent little or no change in non-TXA
patients (Fig. 5), as did clot lysis (LI30, LI45 or ML)
(Table 3). In direct contrast, TXA led to significant in-
creases in CT after the bone cut and surgery compared
to non-TXA patients, with no additional coagulation
changes observed (Table 3, Fig. 5).
FIBTEM
Following surgery, TXA led to a significant increase (1.4
times) in FIBTEM CT compared to non-TXA patients
(p = 0.004) (Table 3). There were no differences in FIBTEM
amplitudes at baseline, after bone cut and at surgery end
Table 2 Preoperative and postoperative (6 weeks) range of
motion (ROM) and patientreported outcome measures (PROM)
in non-TXA and TXA groups
Non-TXA TXA p value
Preoperative:
ROM
Flexion (°) 115 ± 5 121 ± 5 0.411
Extension (°) 5 ± 1 2 ± 1 0.046*
KOOS Total 46 ± 6 41 ± 4 0.470
KOOS Pain 10 ± 2 8 ± 1 0.417
KOOS Function 32 ± 4 29 ± 3 0.457
KOOS Movement 4 ± 0.7 4 ± 0.4 1.000
OKS 22 ± 3 29 ± 3 0.457
EQ5D 3L VAS 64 ± 7 67 ± 4 0.760
Postoperative 6 weeks:
ROM
Flexion (°) 104 ± 5 110 ± 4§ 0.297
Extension (°) 7 ± 1 4 ± 1 0.134
KOOS Total 26 ± 4§ 17 ± 3§ 0.096
KOOS Pain 5 ± 1§ 4 ± 1§ 0.304
KOOS Function 18 ± 3§ 11 ± 2§ 0.098
KOOS Movement 3 ± 0.5 2 ± 0.3§ 0.063
OKS 27 ± 2 32 ± 2 0.097
EQ5D 3L VAS 67 ± 7 75 ± 4 0.339
FJS 62 ± 4 52 ± 6 0.170
Data represents mean ± SEM
KOOS The Knee Injury and Osteoarthritis Outcomes Score, OKS Oxford Knee
Score, EQ5D (3L) EuroQol 5-Dimension 3-Level Assessment, FJS Forgotten Joint
Score. p < 0.05 between non-TXA and TXA group; §p < 0.05 compared with
preoperative value
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(Fig. 5), indicating that fibrinogen concentration remained
unchanged during TKA surgery. TXA also increased max-
imum lysis following the first bone cut (0.5% to 2.8%, p =
0.389) and at surgery end (0.4 to 1.1%. p = 0.140); however,
these differences were not significant (Table 3).
INTEM
In both TXA and non-TXA patients, CT values were
lower than their respective baseline values after the first
bone cut or at surgery end, with no statistical difference
between groups (Table 3). There were also no differences
in clot amplitude at any time point (Fig. 5). Clot lysis
was also comparable between the groups and ranged
from 4.1 to 6.8%, indicating little or no hyperfibrinolysis.
Discussion
Antifibrinolytics are widely used in orthopaedic surgery
to reduce excessive bleeding and minimize transfusion
requirements and re-exploration [5]. In our pilot study
in OA patients undergoing TKA, we report:
 Elevated baseline plasma levels of MCP-1 and TNF-
α relative to healthy, aged-matched human values,
indicating the presence of low-grade systemic in-
flammation prior to surgery.
 After the first bone cut and surgery end, MCP-1,
TNF-α, IL-1β and IL-6 (after surgery) were
significantly increased in TXA compared to non-
TXA patients, with differences further amplified
at postoperative days 1 and 2. TXA appeared to
exacerbate the surgical stress inflammatory
response.
 EXTEM CT was prolonged in TXA patients after
the first bone cut and at surgery end, indicating a
thrombin-slowing effect on clot initiation, despite
little or no change in clot amplitude or fibrinogen
levels.
(See figure on previous page.)
Fig. 3 Plasma levels of inflammatory cytokine/chemokines a MCP-1, b TNF-α, c IL-1RA, d IL-1β, e IL-8, f IL-6, g IL-4, and h IL-10 at baseline, after
bone cuts, surgery end, day 1 and day 2. White square: non-TXA group; black square: TXA group. Data is expressed as mean ± S.E.M. *p < 0.05
compared with corresponding non-TXA patients, ◆p < 0.05 compared to baseline, bone cut, end surgery and day 1, †p < 0.05 compared to
baseline, bone cut and end surgery; #p < 0.05 compared to baseline; ∫p < 0.05 compared to end surgery and day 1; §p < 0.05 compared to bone
cut; ^p < 0.05 compared to baseline and bone cut
a b c d
e f g h
Fig. 4 Area under the curve (AUC) for a MCP-1, b TNF-α, c IL-1RA, d IL-1β, e IL-8, f IL-6, g IL-4, and h IL-10 based on plasma cytokine levels
kinetics from baseline to day 2 postoperative. White square: non-TXA group; black square: TXA group. Data is expressed as mean ± S.E.M. *p < 0.05
compared with corresponding non-TXA patients
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 In TXA patients there was a tendency for increased
FIBTEM maximum lysis during surgery, a finding
that is counter to TXA’s antifibrinolytic effect.
 Maximum lysis in EXTEM and INTEM was < 5%
and < 7%, respectively during surgery, indicating
little or no hyperfibrinolysis, and supported by
similar falls in hemoglobin levels (11–19%) on days
1 and 2 postoperative relative to baseline. These data
question the need for TXA in this surgical setting.
Low-grade inflammation in OA patients
In chronic OA patients, joint inflammation appears to
be expressed systemically as a low-grade inflammatory
state [24–29]. We found that baseline levels of plasma
MCP-1 (CCL2) were up to four times higher than in
aged-matched healthy individuals (95–168 pg/ml) [30,
31], and TNF-α levels almost three times higher than in
normal humans (~ 5 pg/ml) [31, 32] (Fig. 3). MCP-1 is a
chemokine that regulates recruitment of immune cell
traffic from the circulation to sites of inflammation in
OA patients [33, 34], and has been implicated in articu-
lar cartilage degradation and pain [27, 35]. TNF-α is
another potent inflammatory mediator involved in OA
progression [36, 37], contributing to cartilage loss
through its suppression of collagen and proteoglycan
synthesis [24, 36, 38]. Notwithstanding the difficulty of
finding aged-matched healthy human data, our data
suggest the OA patients in the current study presented
with a low-grade systemic inflammation.
TXA exacerbates inflammation in response to surgical
stress
We report significant increases in plasma IL-1β and
TNF-α in TXA patients after the first bone cut and at
surgery end compared to patients that did not receive
TXA (Fig. 3). At the end of surgery, TNF-α and IL-1β
continued to increase in TXA patients and were accom-
panied by significantly higher IL-6 and MCP-1 com-
pared to non-TXA patients (Fig. 3). Although the
cytokine increases were small, they indicate a heightened
inflammatory state in the TXA patients, and heightened
surgical stress response [39–41]. During this early period
in knee or hip surgery, Hall and colleagues have con-
firmed activation of the surgical stress response involv-
ing the hypothalamic–pituitary–adrenal (HPA) axis, with
concomitant increases in plasma cortisol and catechol-
amines [42]. In TKA, the stress response is most likely
activated from multiple neural, hormonal and metabolic
inputs including danger signals (e.g. alarmins) from, soft
tissue and bone resection, and firing of afferent nerves,
that are detected by resident and circulating immune
cells, and the brain respectively [40].
In addition to TXA exacerbating the inflammatory
response during surgery, another key finding was the
Table 3 Clot kinetics and lysis parameters for TXA and non-TXA patients at baseline, after bone cut, and end of surgery as measured
on EXTEM, FIBTEM and INTEM tests
Test Group Time CT (s) CFT (s) Alpha Angle (°) LI30 (%) LI45 (%) ML (%)
EXTEM Non-TXA Baseline 59 ± 3 96 ± 2 72 ± 3 100 ± 0 98.1 ± 0.4 3.1 ± 1.0
Bone Cut 53 ± 1 76 ± 7 76 ± 2* 100 ± 0 97.4 ± 0.5 6.3 ± 0.8*
Surgery End 51 ± 3 75 ± 7 73 ± 3 100 ± 0 98.7 ± 0.3¥ 3.9 ± 0.6¥
TXA Baseline 64 ± 4 70 ± 7 76 ± 1 98.8 ± 1.2 95.6 ± 1.9 7.9 ± 1.9
Bone Cut 59 ± 5 67 ± 6 78 ± 1 99.8 ± 0.3 97.3 ± 0.6 6.5 ± 1.0
Surgery End 65 ± 3¶ 89 ± 14 73 ± 2 100 ± 0 98.3 ± .4 4.4 ± 0.8
FIBTEM Non-TXA Baseline 59 ± 6 884 ± 476 76 ± 1 99.1 ± 0.9 99.3 ± 0.7 1.4 ± 1.3
Bone Cut 53 ± 3 797 ± 604 73 ± 2 100 ± 0 99.9 ± .10 0.5 ± 0.3
Surgery End 49 ± 2 1483 ± 576 67 ± 7 99.9 ± 0.1 100 ± 0 0.4 ± 0.2
TXA Baseline 66 ± 5 1020 ± 480 74 ± 2 100 ± 0 99.5 ± 0.23 1.1 ± 0.4
Bone Cut 54 ± 4* 403 ± 300 76 ± 1* 98.8 ± 0.7 98.3 ± 1.1 2.8 ± 1.3
Surgery End 68 ± 5¶ 480 ± 301 70 ± 2 99.9 ± 0.1 99.8 ± 0.2 1.1 ± 0.4
INTEM Non-TXA Baseline 204 ± 15 104 ± 16 71 ± 2 99.7 ± 0.3 97.7 ± 0.7 4.6 ± 1.0
Bone Cut 164 ± 10* 71 ± 8* 76 ± 2* 99.7 ± 0.2 96.6 ± 0.5 6.3 ± 0.6
Surgery End 162 ± 13* 69 ± 10* 73 ± 2 100 ± 0 98.3 ± 0.4 4.1 ± 0.8
TXA Baseline 170 ± 11 69 ± 8¶ 76 ± 2¶ 99.7 ± 0.1 95.9 ± 0.5 6.8 ± 0.8
Bone Cut 149 ± 8* 65 ± 4 77 ± 1 99.8 ± 0.1 97 ± 0.6* 5.8 ± 0.7
Surgery End 154 ± 12 101 ± 31 73 ± 4 100 ± 0* 97.9 ± 0.4§ 4.8 ± 0.7§
Data represent mean ± SEM. CT clot time, CFT clot formation time, LI lysis index, ML maximum lysis. n = 12 for TXA group; n = 11 for non-TXA group. *p < 0.05
compared with baseline; ¥p < 0.05 compared with Bone Cut; §p < 0.05 compared with baseline and bone cut; ¶p < 0.05 compared non-TXA group
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Fig. 5 EXTEM, FIBTEM and INTEM clot amplitudes at 5 (A5, mm), 15 (A15, mm), 25 min (A25, mm) and Maximum Clot Firmness (MCF, mm) at
baseline, after bone cuts, surgery end, day 1 and day 2. White square: non-TXA group; black square TXA group. Data expressed as mean ± S.E.M.
*p < 0.05 compared to baseline
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apparent amplifying effect of TXA on inflammatory cyto-
kine levels over the first two postoperative days (Fig. 3).
We found increased concentrations of plasma MCP-1,
TNF-α, IL-1β, IL-6, IL-8, and IL-4 and decreased IL-10
levels in patients that received TXA compared to those
that did not. AUC analysis from baseline to postoperative
day 2 showed significantly higher levels of MCP-1, TNF-α
and IL-4 in plasma of TXA than in non-TXA patients
(Fig. 4). The differences in IL-4 are of particular interest
since it is generally regarded as an anti-inflammatory cyto-
kine, similar to IL-10 and IL-13 [43]. In this role, IL-4 is
known to inhibit TNF-α production and IL-1β synthesis
and to increase IL-1RA [43, 44]. However, the opposite
occurred in TXA patients in our study. At postoperative
day 2, plasma TNF-α levels were twofold higher, and
IL-1β was fivefold higher compared to non-TXA patients,
with no change in IL-1RA (Fig. 2).
Recently, Major and colleagues also reported that IL-4
was not purely an anti-inflammatory cytokine, but could
prime macrophages, increase TNF-α and increase in-
flammation [44]. IL-4, in combination with GM-CSF,
can further promote inflammation by increasing differ-
entiation of monocytes into dendritic cells [44]. Bellini
and colleagues also showed that IL-4 can stimulate a
unique circulating leukocyte subpopulation (0.1–0.5%)
of bone marrow-derived stem cells known as fibrocytes
that leave the blood and enter the site of healing and dif-
ferentiate into fibroblasts/myofibroblasts with increased
production of cell matrix components, growth factors,
and inflammatory cytokines [45–47]. Therefore, in the
current study, it is possible that IL-4 contributes to a
heightened systemic inflammatory response observed in
TXA patients (Figs 3, 4).
TXA prolonged clot times during surgery and had no
effect on clot lysis
In our study, baseline ROTEM clotting parameters for
OA patients were similar to normal healthy individuals
[22, 31, 32, 48]. In contrast to a low-grade inflammatory
state at baseline in our OA groups, it appears that there
were no apparent coagulation defects. However, after the
first bone cut and surgery end, the non-TXA patients
had decreased EXTEM, FIBTEM and INTEM clot times
(9 to 21% falls relative to baseline) (Table 3), indicating
increased thrombin availability. This was further sup-
ported by 22 and 34% decreases in EXTEM CFT and
INTEM CFT, respectively, with little or no change in
α-angles (Table 3). The shift in CT and CFT was associ-
ated with no effect on clot amplitude or strength (Fig. 3)
but a twofold increase (3.1 to 6.3%) in maximum lysis in
EXTEM (p = 0.021) and 1.4 times (4.6 to 6.3%) in
INTEM after the bone cut (Table 3). Notably, the in-
creases in fibrinolysis in non-TXA patients were within
the range of normal values, with 15% often used as a
guide to indicate hyperfibrinolysis [20, 22]. Thus, in
non-TXA patients, surgical stress appeared to decrease
clot times and thrombin availability without changes in
other ROTEM parameters.
However, in TXA patients, EXTEM CT at surgery end
was significantly higher (1.3-fold) than non-TXA pa-
tients, indicating that TXA during surgical stress has a
thrombin-slowing effect (Table 3). We reported a similar
finding in cardiac surgery after a sternotomy with TXA
having a twofold increase in CT (all tests) [16]. In that
study, we speculated that TXA may (1) reduce the rate
of prothrombin-thrombin conversion, or (2) inhibit one
or more of the polypeptide cleavage reactions, and
thereby slow the fibrinogen to fibrin conversion [16].
Interestingly, since TXA is a lysine analogue, reducing
the prothrombin-thrombin conversion is possible since
the kringle-2 domain of the prothrombin complex is rich
in lysine residues, and TXA may partially block these
sites thus reducing thrombin production. In contrast to
our cardiac surgery study, both TXA and non-TXA pa-
tients had significantly decreased INTEM CT during
surgery in the current study (Table 3), highlighting dif-
ferences in TXA with clotting factors or pathway selec-
tion. Importantly, and in agreement with our previous
study, we found no difference in EXTEM or INTEM clot
lysis in TXA and non-TXA patients. This finding sug-
gests that perhaps the beneficial effect of TXA published
in a large number of randomized controlled trials involv-
ing nearly 1 million patients [10] might not be reflected
by the absence of evidence of hyperfibrinolysis with
ROTEM (and TEG). In addition, we found no difference
in hemoglobin levels between the groups postoperatively
(Table 1), suggesting blood loss was similar for both
TXA and non-TXA patients after TKA surgery.
TXA paradoxically increases FIBTEM maximum lysis after
bone cut and surgery
Another interesting trend observed in the present study
was that TXA increased maximum lysis in FIBTEM
after the bone cut (5-fold higher) and the end of sur-
gery (~ 3-fold higher) compared to non-TXA patients
(Table 3). The FIBTEM test is EXTEM with platelet
inhibition (see Fig. 2), and these paradoxical results
suggest that TXA weakens, not strengthens, the fibrin
network in the absence of platelet contribution. This
pro-fibrinolytic effect of TXA was not due to falling
levels of fibrinogen because there was no change in
FIBTEM amplitudes (Fig. 5). Currently, we do not
know the underlying mechanisms for this effect of
TXA on maximum lysis. Platelets normally support
the formation of a dense, stable fibrin network from
αIIbβ3 integrin interactions and the fibrin network
[49]. In the absence of platelets, it appears that lysine
residues play a role in securing fibrin density and
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stability in the FIBTEM clot, which is decreased in
the presence of TXA. While this observation may be
clinically silent under normal hematological condi-
tions, it has the potential to become a significant
problem in major surgery or various trauma states,
where platelet numbers may decrease or platelet acti-
vation is impaired numbers or function.
Potential clinical significance: a call for precision-based
medicine
An important finding in the present study was that there
appeared to be no clinical advantage of using TXA in our
patient group undergoing elective TKA. Without evidence
of hyperfibrinolysis (Table 3), there is no clinical justifica-
tion for TXA use because there is no excessive bleeding
[4]. In addition, TXA administration appeared to have a
potentially untoward pro-inflammatory effect during and
after surgery, which may be linked to a more pronounced
TXA-induced stress response to the trauma of surgery.
This may be clinically significant since Galvez and col-
leagues recently demonstrated that patients with OA
already have a diminished ability to tolerate surgical stress
[29], which the authors associated with a pre-existing
low-grade chronic systemic inflammation [40, 42]. Our
study further underscores a number of outstanding ques-
tions on TXA use in major surgery: (1) Would a single
dose administration of TXA have less effect to increase
inflammation and stress response to surgery? (2) What la-
boratory tests should be used to drive TXA use in elective
or emergency surgery? and (3) What is the scientific basis
for using TXA in orthopaedic surgery? In our view, TXA
should not be viewed as a one-size-fits-all approach to
elective surgery; rather it should be incorporated into a
more precision-based set of guidelines [4, 50, 51]. The po-
tential harmful effects of TXA on promoting inflamma-
tion warrant further investigation.
Limitations of the study
A major limitation of our pilot study was its lack of
randomization, blinding and small patient numbers. Our
postoperative period was also limited and requires ex-
tension beyond day 2 when joint swelling is at a max-
imum, and 10–14 days when adhesions begin to form.
Given surgically induced inflammation is also linked to
postoperative pain and fragmented sleep patterns follow-
ing TKA [42, 52, 53], these additional metrics should be
included in future studies. Another limitation was that
we did not measure plasma stress hormones, which may
be higher in patients with higher inflammatory status
during and following surgical stress [39–42]. We also do
not know the effect of the cocktail components that
were injected around the knee after the bone cut on
TXA’s effect to change some ROTEM parameters and/or
inflammatory markers. In vitro studies are also required
to examine TXA’s effect on fibrinogen with and without
platelets, and role of lysine residues using rapid-kinetic
monitoring, X-ray crystallography, nuclear magnetic
resonance and electron microscopy techniques. Notwith-
standing these limitations, our study provides a spring-
board for a larger prospective, randomized trial to
further elucidate the effects of TXA on inflammation
and the surgical stress response to TKA, the outcomes
of which may have implications for other pediatric and
adult elective and emergency surgeries.
Conclusions
In moderate-to-severe OA patients, TXA led to pro-
longation of EXTEM CT after the first bone cut and end
of surgery compared to non-TXA patients, despite little
or no change in clot strength or fibrinogen levels. Max-
imum lysis in EXTEM and INTEM was < 10% in both
TXA and non-TXA patients, indicating little or no
hyperfibrinolysis and thus questioning the need for TXA
in our patient group. TXA was also associated with
increased systemic inflammation, with rising plasma
levels of proinflammatory cytokines in the first 2 days
after TKA surgery.
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